Marinus Pharmaceuticals — American Epilepsy Society Annual Meeting 2019
28 slides from Marinus Pharmaceuticals's conference presentation, Dec 9, 2019

Slide 1: IV Ganaxolone in Refractory Status Epilepticus: Phase 2 Clinical Data & Phase 3 Planning
NASDAQ: MRNS @ MarinusPharma IV Ganaxolone in Refractory Status Epilepticus (RSE): Phase 2 Clinical Data & Phase 3 Planning December 9, 2019 American Epilepsy Society Annual Meeting

Slide 2: Safe Harbor Statement
©2019 Marinus Pharmaceuticals. All Rights Reserved. Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management made

Slide 3: Refractory Status Epilepticus is a Neurological Emergency
©2019 Marinus Pharmaceuticals. All Rights Reserved. Mortality Overall mortality is ~17 - 39% in RSE patients 3,7 Mean RSE duration (in hrs.) between survivors and non - survivors was found to be 88.9 and 120.3 (p=0.002) 3 Hospital stay Patients that achieve SE cessation within 1 or 12 hours (convuls

Slide 4: Goals of a new treatment for RSE
©2019 Marinus Pharmaceuticals. All Rights Reserved. Goals of a new treatment for RSE Rapid cessation of SE Maintenance of seizure control over study period Prevent patient progression towards escalation of treatment (IV anesthetics) Goals of a New Therapy for the Treatment of RSE Benzodiazepine Admi

Slide 5: Ganaxolone (GNX) Mechanism of Action
©2019 Marinus Pharmaceuticals. All Rights Reserved. Ganaxolone (GNX) Mechanism of Action • GNX is a synthetic analog of endogenous allopregnanolone and a potent positive allosteric modulator of GABA A - receptors. • GNX targets unique binding sites on GABA A - receptors that are not susceptible to t

Slide 6: Rationale for IV GNX for the Treatment of RSE
©2019 Marinus Pharmaceuticals. All Rights Reserved. Rationale for IV GNX for the Treatment of RSE 6 Ganaxolone has demonstrated a broad range of anticonvulsant and psychotherapeutic responses Benzodiazepines are effective in treating acute seizures but not RSE • Benzodiazepines are positive alloster

Slide 7: Key Differences in GNX (RSE) Trial and STATUS Trial (SRSE)
©2019 Marinus Pharmaceuticals. All Rights Reserved. Key Differences in GNX (RSE) Trial and STATUS Trial (SRSE) 7 STATUS in SRSE GNX in RSE Patient Population SRSE: medically more difficult to treat than RSE; seizures less likely to respond than RSE RSE: More likely to respond than SRSE via engagemen

Slide 8: RSE Trial Design
©2019 Marinus Pharmaceuticals. All Rights Reserved. Treatment Period Loading Dose Maintenance Taper Phase 2 RSE Trial Design Diagnosis of convulsive or non - convulsive SE Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics Bolus plus continuous infusion 2 - 4 day

Slide 9: Baseline Characteristics
©2019 Marinus Pharmaceuticals. All Rights Reserved. Baseline Characteristics 9 17 patients enrolled • 8 males, 9 females • Mean age: 57 years old (range: 23 - 88) Types of SE • 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE → NCSE History of Epilepsy • 7 (41%) yes, 10 (59%) no Mean # of failed IV AEDs (incl

Slide 10: Preliminary Data – Prior Two Failed Antiseizure Drugs
©2019 Marinus Pharmaceuticals. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 0 6 12 18 24 Patient # T i m e P r i o r t o G N X I n i t a t i o n ( h r s ) ( t o p o f e a c h b a r i n d i c a t e s w h e n A S D w a s i n i t i a t e d ) 1st Prior ASD 2nd Prior ASD LAC LEV LOR LAC

Slide 11: Ganaxolone Provides Rapid Onset and Durability of Efficacy
©2019 Marinus Pharmaceuticals. All Rights Reserved. Ganaxolone Provides Rapid Onset and Durability of Efficacy 11 Cohort No escalation to IV anesthetics within 24 hrs from infusion initiation (Primary Endpoint) Status - free through 24 hrs from infusion initiation No escalation to additional IV AEDs

Slide 12: PK/PD Relationship and Rationale for Target Dose
©2019 Marinus Pharmaceuticals. All Rights Reserved. PK/PD Relationship and Rationale for Target Dose 12 0 3 6 9 0 200 400 600 800 1,000 Time (hrs) G N X P l a s m a C o n c e n t r a t i o n ( n g / m L ) Low (model) Low Dose Patient Recurrence of abnormal EEG activity Acute maintenance of GNX plasm

Slide 13: PK/PD Relationship and Rationale for Target Dose
©2019 Marinus Pharmaceuticals. All Rights Reserved. PK/PD Relationship and Rationale for Target Dose 13 Dashed lines are PK models 0 6 12 18 24 0 200 400 600 800 1,000 Time (hrs) G N X P l a s m a C o n c e n t r a t i o n ( n g / m L ) Low 500mg/day Medium 650mg/day Target 713mg/day Seizure Burden

Slide 14: Phase 2 Efficacy and Safety
©2019 Marinus Pharmaceuticals. All Rights Reserved. Prevented escalation to IV anesthetics No patients progressed to IV anesthetics during first 24 hours (100% achievement of primary endpoint) Rapid onset of action IV GNX achieved SE cessation at median of 5 minutes (n=15 evaluable) and ~80% seizure

Slide 15: IV Ganaxolone Safety Summary
©2019 Marinus Pharmaceuticals. All Rights Reserved. 2 related in 2 patients • 2 severe sedation 13 Related in 7 patients • 6 mild (2 hypotension, 2 somnolence, 1 urinary retention, 1 hypercarbia) • 5 moderate (4 somnolence; 1 hypercarbia) • 2 severe (2 sedation) IV Ganaxolone Safety Summary 15 10 SA

Slide 16: Phase 3 Planning
©2019 Marinus Pharmaceuticals. All Rights Reserved. Phase 3 Planning 16 Study Design Randomized, placebo - controlled (adjunctive to standard - of - care) clinical trial Target Patient Population RSE patients with similar baseline characteristics (etiology, # of failed IV AED’s, etc.) to the Phase 2

Slide 17: Tuberous Sclerosis Complex – Rare, Serious Genetic Disorder
©2019 Marinus Pharmaceuticals. All Rights Reserved. Cause Defect or mutation of TSC1 and/or TSC2 genes Symptoms Benign tumors, seizures, cognitive impairment, behavioral problems, skin abnormalities Prevalence ~25K patients with refractory epilepsy Treatments Limited approved treatments Mechanistic

Slide 18: Phase 2 Open-Label Clinical Trial Design in TSC
©2019 Marinus Pharmaceuticals. All Rights Reserved. PART A PART B Base (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol* Phase 2 Open - Label Clinical Trial Design in TSC • n = 30 •

Slide 19: SE & RSE Patient Volume, Pricing & Market Overview
NASDAQ: MRNS @ MarinusPharma SE & RSE Patient Volume, Pricing & Market Overview Investor Breakfast Meeting AES December 9, 2019

Slide 20: Status Epilepticus (SE) Patient Population
©2019 Marinus Pharmaceuticals. All Rights Reserved. - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Status (SE) in Seven Major Markets United States United Kingdom Germa

Slide 21: Refractory Status Epilepticus (RSE) Patient Population
©2019 Marinus Pharmaceuticals. All Rights Reserved. - 5,000 10,000 15,000 20,000 25,000 30,000 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Refractory Status (RSE) in Seven Major Markets United States United Kingdom Germany Italy France

Slide 22: SE represents a high degree of unmet clinical need and substantial commercial opportunity
©2019 Marinus Pharmaceuticals. All Rights Reserved. SE represents a high degree of unmet clinical need and substantial commercial opportunity SE Treatment Dynamics & Unmet Need SE treatment response rates of 50% - 70% with SOC (per med literature, KOLs, MR) • 30% - 50% of SE patient will not respond

Slide 23: SE Market Expansion Potential
©2019 Marinus Pharmaceuticals. All Rights Reserved. GNX has the potential to move up in the treatment continuum for utilization in some segment of the SE population SE Market Expansion Potential Key drivers for the potential use of GNX in SE: • Potential to conduct Phase IV clinical studies to demon

Slide 24: GNX Pricing Payer Primary Market Research – U.S.
©2019 Marinus Pharmaceuticals. All Rights Reserved. Pharmacy Directors, NEUROs, and Payers recommended a $25,000 - $50,000 range for a novel RSE agent GNX Pricing Payer Primary Market Research – U.S. 24 Pricing a novel RSE agent below the current DRG ensures that hospitals will be reimbursed without

Slide 25: GNX SE/RSE Reimbursement Dynamics
©2019 Marinus Pharmaceuticals. All Rights Reserved. Shorten hospital stay Bypass ICU Reduce adverse events • Rapid and sustained seizure control • No recovery/rehab from sedation • Bolus delivery suitable for the ER • No need for intubation • No intensive cardiovascular monitoring • Avoid frequent c

Slide 26: SE/RSE DRG Summary
©2019 Marinus Pharmaceuticals. All Rights Reserved. SE/RSE DRG Summary* DRG Code Description Mean Covered Charges DRG - 100 Seizure with MCC** $59,800 DRG - 101 Seizure w/or MCC** $30,890 Unweighted Average $45,345 *Publicly available data from CMS for SE – needs to be further refined through additi

Slide 27: RSE Market By Territory: $1B+ opportunity
©2019 Marinus Pharmaceuticals. All Rights Reserved. RSE Market By Territory: $1B+ opportunity $- $200.00 $400.00 $600.00 $800.00 $1,000.00 $1,200.00 Low Price High Price RSE Market Opportunity By Region US EU5 Japan RSE market is valued between $1B - $2B at premium prices in 2019 based on projected

Slide 28: US RSE Market Size & Value
©2019 Marinus Pharmaceuticals. All Rights Reserved. US RSE Market Size & Value 28 Refractory Status Epilepticus - Disease Coverage, Pipeline and Market Analysis, Market & Epidemiology Forecast - 2029 – Quintana Res earch RSE represents a substantial peak revenue opportunity for GNX ranging between ~
Source: SEC EDGAR · 8-K filed Dec 9, 2019
More decks from Marinus Pharmaceuticals Inc
Investor Presentation (November 2024)26 slides · Nov 12, 2024
Investor Presentation (August 2024)37 slides · Aug 13, 2024
Investor Presentation (June 2024)41 slides · Jun 17, 2024
Investor Presentation (May 2024)39 slides · May 8, 2024
Investor Presentation (March 2024)51 slides · Mar 5, 2024
Investor Presentation (January 2024)53 slides · Jan 4, 2024